Focus Myocardial Infarction

Aposcience AG has identified APO-1 (APOSECTM), derived from the secretome of irradiated, apoptotic peripheral blood mononuclear cells (PBMCs) as superbly efficacious in reducing infarct size and maintaining left ventricular function in animal models of myocardial infarction (MI). These models tested MI with and without reperfusion, including one of ischemia and reperfusion.

These data are predictive for the prevention of adverse remodeling following revascularization of an acute MI. The target population are those over 700,000 patients worldwide who undergo reperfusion treatment for acute ST-elevation myocardial infarction. If APO-1 (APOSECTM) proves effective in clinical trials, the market potential is estimated at 1 – 2 billion Euros annually.

Latest News
Aug
31

Approval of DSMB for Lead In-Phase and Go-Ahead for MARSYAS II Main Study

[more]

May
27

Approval for clinical phase II study in DFU by German health agency PEI

[more]